atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
08 août 2023 16h02 HE
|
atai Life Sciences
NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
American Psychedelic Practitioners Association and BrainFutures Publish First Professional Practice Guidelines for Psychedelic-Assisted Therapy
08 août 2023 08h00 HE
|
The American Psychedelic Practitioners Association
WASHINGTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- The American Psychedelic Practitioners Association (APPA), the leading organization focused on safely integrating psychedelics into the US healthcare...
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
01 août 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
31 juil. 2023 08h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
20 juil. 2023 09h07 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
Cannabis Science Conference to debut in Providence, R.I., with renewed focus on analytical science, medical cannabis, cultivation and psychedelics
18 juil. 2023 16h43 HE
|
Cannabis Science Conference
PROVIDENCE, R.I., July 18, 2023 (GLOBE NEWSWIRE) -- Cannabis Science Conference (CSC), the premier cannabis science conference focusing on analytical science, medical cannabis, cultivation and...
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)
06 juil. 2023 08h42 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
Cortexa Makes First Drug Order for Australian Commercial Market
04 juil. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
Momentum Events Celebrates Historic Conference, Psychedelic Science 2023
23 juin 2023 14h47 HE
|
Psychedelic Science 2023
DENVER, June 23, 2023 (GLOBE NEWSWIRE) -- Momentum Events, one of the nation’s leading event production companies with a specialization in producing conferences and trade shows focused on emerging...
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
22 juin 2023 08h00 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
SAN JOSE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) today announced that the Steven & Alexandra Cohen Foundation has awarded MAPS...